Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Gam1983/Getty Images
Hey, I am a multifaceted professional excelling in the realms of blogging, YouTube content creation, and entrepreneurship.
With a passion for sharing knowledge and inspiring others, I established a strong presence in the digital sphere through his captivating blog articles and engaging video content.